Home Tags CDMO

Tag: CDMO

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement

Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO) and San Francisco-based biotech Bolt Bioterapeutics have signed a production agreement in which Piramal...
Ajinomoto Bio-Pharma Services has established a high-containment bioconjugate manufacturing facility for the production and fill and finish of Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC). The facility, developed by SKAN AG, has been designed for safe handling and manipulation of very low OEL compounds (down to 1 ng/m3) while maintaining aseptic conditions and cGMP compliance. Photo courtesy: © 2020 Ajinomoto Bio-Pharma.

Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality...

Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies...
MabPlex has started operations of two cell culture production lines of GE brand 2,000-liter single-use bioreactors. Photo Courtesy: MabPlex USA, Inc.

MabPlex Launches Two New Cell Culture Production Lines and Plans Further...

MabPlex International, a fully integrated, Contract Development and Manufacturing Organization (CDMO) with sites in China (Yantai and Shanghai) and the United States (San Diego),...
Featured Image: MabPlex Building, Yantai, Shandong, China. Courtesy: © 2017 MabPlex. Used with permission.

Frost & Sullivan Awards MabPlex with the 2019 Global Growth Excellence...

Based on its recent analysis of the global contract manufacturing services market for antibody-drug conjugate or ADCs, Frost & Sullivan has awarded China-headquarter MabPlex...
Seattle Genetics

5 Things You Need To Know This Week About ADCs –...

This is the second article in my series of updates about the goings on in the world of ADCs over the last two weeks....
Photo: Exhibition - Bird's Eye Overview. The 15th annual PEGS: The Essential Protein Engineering Summit brought more than 2,700 world-renowned experts, visionaries, and influencers from top pharma, biotech, academic, and government institutions to the Seaport World Trade Center in Boston, MA this past April 8-12, 2019, setting record-breaking attendance. Photo courtesy: CHI/PEGS

PEGS 2019: Using Economic Modelling In the ADC Manufacturing Supply Chain

Antibody-drug conjugates have become a strong and promising strategy for the treatment of cancer, and, potentially emerging in therapeutic areas outside oncology and hematology.Today,...
Courtesy: Fotolia

The Evolving Market for Antibody-drug Conjugates

The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat...

Rapidly Expanding MabPlex International Secures U.S. $ 59.1 Million Series A...

In an announcement made to the international business and financial press, MabPlex International, a global Contract Development and Manufacturing Organization or CDMO based in...

Evolution of Antibody-Drug Manufacturing

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and...

Poor Aggregation: Failing ADC Targets, Long Delays in Development and Wasted...

During all stages of development, including expression, refolding, downstream processing, formulation, sterilization, and storage, biotherapeutic proteins are subjected to aggregation and degradation.  In the...